Daclizumab Biosimilar - Research Grade

Daclizumab Biosimilar - Research Grade, Human IgG1

Target: CD25.

Specificity: Detects human CD25. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Daclizumab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: RUO daclizumab biosimilar is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis. Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

Concentration: 5mg/ml.

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE.

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

• Artikelnummer: ICH5021-100MG
• Hersteller: Ichorbio
• Hersteller Artikelnummer: ICH5021-100MG
• Green Labware: Nein
• Verpackungseinheit: 100mg
• Mengeneinheit: STK
• Reaktivität: Human
• Klonalität: Monoclonal
• Methode: Functional Assay
• Isotyp: Human IgG1